Edition:
United Kingdom

Amgen Inc (AMGN.OQ)

AMGN.OQ on NASDAQ Stock Exchange Global Select Market

195.47USD
13 Sep 2019
Change (% chg)

$1.47 (+0.76%)
Prev Close
$194.00
Open
$194.41
Day's High
$196.63
Day's Low
$194.41
Volume
794,265
Avg. Vol
1,170,586
52-wk High
$211.89
52-wk Low
$166.30

Select another date:

Sun, Sep 8 2019

Amgen drug shrinks lung cancer tumors in half of patients: study

An experimental Amgen Inc drug that targets a specific genetic mutation reduced tumor size in around half of advanced lung cancer patients given the highest dose in a small, early-stage trial, the company said on Sunday.

Amgen drug shrinks lung cancer tumors in half of patients -study

Sept 8 An experimental Amgen Inc drug that targets a specific genetic mutation reduced tumor size in around half of advanced lung cancer patients given the highest dose in a small, early-stage trial, the company said on Sunday.

Patent court to review Alexion's Soliris patents on Amgen challenge

The U.S. patent office will review patents on Alexion Pharmaceuticals Inc's blood disorder treatment Soliris, after Amgen Inc challenged them, court filings showed on Friday.

UPDATE 2-Patent court to review Alexion's Soliris patents on Amgen challenge

Aug 30 The U.S. patent office will review patents on Alexion Pharmaceuticals Inc's blood disorder treatment Soliris, after Amgen Inc challenged them, court filings showed on Friday.

Patent court to review Alexion's Soliris patents on Amgen challenge - filings

Aug 30 The U.S. patent office will review three patents on Alexion Pharmaceuticals Inc's drug Soliris, after rival Amgen Inc filed a petition challenging them, court filings showed on Friday.

U.S. judge rules for Regeneron, Sanofi in Amgen cholesterol drug patent fight

A U.S. judge on Wednesday set aside a jury verdict that found Amgen Inc patents on its cholesterol drug Repatha were valid, handing a victory to Regeneron Pharmaceuticals Inc and Sanofi SA, which sells a rival drug.

U.S. judge rules for Regeneron, Sanofi in Amgen cholesterol drug patent fight

A U.S. judge on Wednesday set aside a jury verdict that found Amgen Inc patents on its cholesterol drug Repatha were valid, handing a victory to Regeneron Pharmaceuticals Inc and Sanofi SA , which sells a rival drug.

UPDATE 3-U.S. judge rules for Regeneron, Sanofi in Amgen cholesterol drug patent fight

Aug 28 A U.S. judge on Wednesday set aside a jury verdict that found Amgen Inc patents on its cholesterol drug Repatha were valid, handing a victory to Regeneron Pharmaceuticals Inc and Sanofi SA, which sells a rival drug.

U.S. judge rules for Sanofi in Amgen patent fight

Aug 28 A U.S. judge on Wendesday largely set aside a jury verdict that Amgen Inc patents on its cholesterol drug Repatha were valid, handing a victory to Regeneron Pharmaceuticals Inc and Sanofi SA. (Reporting by Jan Wolfe; editing by Jonathan Oatis)

Amgen to buy Celgene psoriasis drug Otezla for $13.4 billion

Amgen Inc will buy Celgene Corp's psoriasis drug Otezla for $13.4 billion in cash, clearing the way for Bristol-Myers Squibb to go ahead with its $74 billion deal for Celgene by the end of the year.

Select another date: